Bide Pharmatech Co. Ltd. A

688073 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

63.88CNY-3.36 (-5.00%)

Price History

Full chart

Market Stats

Previous Close67.24

Open66.21

Day Range63.43 – 67.09

52-Week Range43.21 – 88.88

Volume3.46M

Market Cap6.96B

P/E (TTM)36.83

Forward P/E0.00

EPS2.08

Dividend Yield1.51%

Beta0.58

50-Day Avg63.69

200-Day Avg59.33

About

Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of drug molecule building blocks and scientific reagents in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. Bide Pharmatech Co., Ltd. was founded in 2007 and is based in Shanghai, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMs. Lan Dai
Employees734
HeadquartersBuilding 3, Shanghai, China, 200433, China
Websitehttps://www.bidepharm.com

Leadership

Ms. Lan DaiGM & Chairman · b. 1972
Kun WangCFO & Accounting Supervisor
Xuan WangBoard Secretary · b. 1985
Ms. Weiqing LuCore technical personnel · b. 1986

Financials

Income Statement

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	391.46M	606.22M	833.83M	1.09B	1.10B	1.32B
Growth (%)	-	+54.86%	+37.55%	+30.94%	+0.93%	+20.13%
Cost of Revenue	178.60M	306.39M	463.80M	655.12M	646.52M	734.24M
Gross Profit	212.86M	299.83M	370.03M	436.74M	455.49M	589.57M
Gross Margin	54.38%	49.46%	44.38%	40.00%	41.33%	44.54%
Operating Expense	121.41M	175.77M	203.83M	307.97M	296.87M	347.92M
Operating Income	91.45M	124.06M	166.20M	128.77M	158.63M	241.65M
Operating Margin	23.36%	20.46%	19.93%	11.79%	14.39%	18.25%
EBITDA	-	-	191.77M	155.46M	180.02M	231.60M
EBITDA Margin	-	-	23.00%	14.24%	16.34%	17.49%
Net Income	59.00M	97.57M	145.97M	109.57M	117.43M	151.74M
Net Income Margin	15.07%	16.10%	17.51%	10.04%	10.66%	11.46%
R&D	21.49M	34.88M	46.07M	63.23M	59.05M	62.72M
R&D as % of Total Revenue	5.49%	5.75%	5.53%	5.79%	5.36%	4.74%
Interest Expense	1.87M	924.13K	2.16M	2.53M	3.32M	5.80M
Interest Expense % of Total Revenue	0.48%	0.15%	0.26%	0.23%	0.30%	0.44%

Balance Sheet

Currency: CNY	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	-	531.90M	906.13M	2.36B	2.42B	2.42B	2.52B
Total Liabilities	-	167.64M	277.27M	283.05M	325.49M	390.91M	471.40M
Total Equity	-	364.26M	628.86M	2.08B	2.09B	2.03B	2.05B
Cash	-	91.41M	193.13M	1.51B	1.27B	1.11B	941.48M

Cash Flow

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	3.65M	-64.88M	29.87M	-57.39M	158.31M	28.32M
Capital Expenditure	37.73M	29.20M	38.41M	61.08M	88.35M	24.28M
Free Cash Flow	-34.08M	-94.09M	-8.54M	-118.47M	69.97M	4.04M
Dividends Paid	23.87M	188.01K	83.58K	100.03M	79.88M	79.79M
FCF to OCF	-935.03%	145.01%	-28.59%	206.43%	44.20%	14.26%
Dividend Paid to FCF	-70.04%	-0.20%	-0.98%	-84.44%	114.17%	1974.76%

Earnings

Report Date	Jan 13, 2023	Apr 19, 2023
EPS Estimate	-	-
EPS Actual	0.74	0.57
Surprise	-	-
Timing	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap6.96B

Enterprise Value6.45B

Trailing P/E36.83

Forward P/E0.00

Price / Sales5.05

Price / Book3.56

EPS2.08

Book Value23.93

Revenue (TTM)1.38B

Gross Profit (TTM)612.44M

EBITDA250.38M

Profit Margin13.17%

Operating Margin19.47%

Return on Equity9.06%

Return on Assets5.86%

Shares Outstanding90.88M

Shares Float32.93M

Beta0.58

Dividend Yield1.51%

Dividend Rate1.16

Payout Ratio55.77%

Dividends

20261×

1.16Jun 10, 2026

20251×

0.90Jun 9, 2025

20241×

0.90Jun 26, 2024

20231×

1.54May 25, 2023

Stock Splits

May 25, 20231.4:1